{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:08Z","timestamp":1740144008246,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40256-019-00341-9","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T03:44:41Z","timestamp":1551843881000},"page":"421-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study"],"prefix":"10.1007","volume":"19","author":[{"given":"Anna","family":"Rago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-4686","authenticated-orcid":false,"given":"Andrea Antonio","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cassese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Arena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina Giada","family":"Magliocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Golino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"issue":"5","key":"341_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/heart.86.5.516","volume":"86","author":"S Stewart","year":"2001","unstructured":"Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew\/Paisley study. Heart. 2001;86(5):516\u201321.","journal-title":"Heart"},{"issue":"9658","key":"341_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","volume":"373","author":"T Watson","year":"2009","unstructured":"Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow\u2019s triad revisited. Lancet. 2009;373(9658):155\u201366.","journal-title":"Lancet"},{"issue":"3","key":"341_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0735-1097(00)01178-5","volume":"37","author":"AL Klein","year":"2001","unstructured":"Klein AL, Murray RD, Grimm RA, et al. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol. 2001;37(3):691\u2013704.","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"341_CR4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J"},{"key":"341_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"issue":"11","key":"341_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","volume":"63","author":"G Flaker","year":"2014","unstructured":"Flaker G, Lopes RD, Al-Khatib SM. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"341_CR7","first-page":"1","volume":"00","author":"MD Ezekowitz","year":"2018","unstructured":"Ezekowitz MD, Pollack CV, Jr Halperin JL, et al. Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;00:1\u201313.","journal-title":"Eur Heart J"},{"issue":"4","key":"341_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/europace\/eux116","volume":"20","author":"s It\u00e4inen","year":"2018","unstructured":"It\u00e4inen s, Lehto M, Vasankari T T, et al. Non-vitamin K antagonist oral in atrial fibrillation patients undergoing elective cardioversion. Europace. 2018;20(4):565\u20138.","journal-title":"Europace."},{"issue":"3","key":"341_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1060028017737095","volume":"52","author":"CM Gibson","year":"2018","unstructured":"Gibson CM, Basto AN, Howard ML. Direct oral anticoagulants in cardioversion: a review of current evidence. Ann Pharmacother. 2018;52(3):277\u201384. \n                    https:\/\/doi.org\/10.1177\/1060028017737095\n                    \n                  \n                           (Epub 2017 Oct 12).","journal-title":"Ann Pharmacother."},{"issue":"4","key":"341_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost"},{"key":"341_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0124-5","author":"W Saliba","year":"2015","unstructured":"Saliba W. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation. Am J Cardiovasc Drugs. 2015. \n                    https:\/\/doi.org\/10.1007\/s40256-015-0124-5\n                    \n                  .","journal-title":"Am J Cardiovasc Drugs"},{"key":"341_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-013-0062-z","author":"C Gonzalez-Quesada","year":"2014","unstructured":"Gonzalez-Quesada C, Giugliano R. Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. Am J Cardiovasc Drugs. 2014. \n                    https:\/\/doi.org\/10.1007\/s40256-013-0062-z\n                    \n                  .","journal-title":"Am J Cardiovasc Drugs"},{"issue":"20","key":"341_CR13","first-page":"3961","volume":"19","author":"V Russo","year":"2015","unstructured":"Russo V, Bianchi V, Cavallaro C, et al. Efficacy and safety of dabigatran in a \u201creal-life\u201d population at high thromboembolic and hemorrhagic risk: data from Monaldi Care registry. Eur Rev Med Pharmacol Sci. 2015;19(20):3961\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"341_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/2042098616673990","volume":"8","author":"V Russo","year":"2017","unstructured":"Russo V, Rago A, Proietti R, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017;8(2):67\u201375.","journal-title":"Ther Adv Drug Saf"},{"issue":"11","key":"341_CR15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2459\/JCM.0000000000000548","volume":"18","author":"V Russo","year":"2017","unstructured":"Russo V, Rago A, D\u2019Onofrio A, et al. The clinical performance of dabigatran in the Italian real-life experience. J Cardiovasc Med (Hagerstown). 2017;18(11):922\u20133.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"2","key":"341_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-017-1599-5","volume":"45","author":"V Russo","year":"2018","unstructured":"Russo V, Rago A, Papa AA, et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2018;45(2):206\u201312.","journal-title":"J Thromb Thrombolysis."},{"issue":"6","key":"341_CR17","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/europace\/eux127","volume":"20","author":"AJ Camm","year":"2018","unstructured":"Camm AJ, Turpie AGG, Hess S, et al. Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. Europace. 2018;20(6):e87\u201395.","journal-title":"Europace."},{"key":"341_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijcard.2016.09.022","volume":"224","author":"V Russo","year":"2016","unstructured":"Russo V, Di Napoli L, Bianchi V, et al. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: the MonaldiVert real life experience. Int J Cardiol. 2016;224:454\u20135.","journal-title":"Int J Cardiol"},{"key":"341_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-018-0279-y","author":"AR Hospodar","year":"2018","unstructured":"Hospodar AR, Smith KJ, Zhang Y, Hernandez I. Comparing the cost effectiveness of non-vitamin k antagonist oral anticoagulants with well-managed warfarin for stroke prevention in atrial fibrillation patients at high risk of bleeding. Am J Cardiovasc Drugs. 2018. \n                    https:\/\/doi.org\/10.1007\/s40256-018-0279-y\n                    \n                  .","journal-title":"Am J Cardiovasc Drugs"},{"key":"341_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-016-0204-1","author":"K Athanasakis","year":"2017","unstructured":"Athanasakis K, Boubouchairopoulou N, Karampli E. Cost effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with atrial fibrillation: a Greek perspective. Am J Cardiovasc Drugs. 2017. \n                    https:\/\/doi.org\/10.1007\/s40256-016-0204-1\n                    \n                  .","journal-title":"Am J Cardiovasc Drugs"},{"key":"341_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijcard.2015.02.075","volume":"184","author":"G Stabile","year":"2015","unstructured":"Stabile G, Russo V, Rapacciuolo A, et al. Transesophagealechocardiograpy in patients with persistent atrial fhibrillation undergoing electrical cardioversion on new oral anticoagulants: a multi center registry. Int J Cardiol. 2015;184:283\u20134.","journal-title":"Int J Cardiol"},{"key":"341_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2017.07.048","volume":"249","author":"E Bertaglia","year":"2017","unstructured":"Bertaglia E, Anselmino M, Zorzi A, et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J Cardiol. 2017;249:179\u201383.","journal-title":"Int J Cardiol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-019-00341-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:10:06Z","timestamp":1583367006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-019-00341-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00341-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"6 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anna Rago, Andrea Antonio Papa, Antonio Cassese, Giulia Arena, Maria Cristina Giada Magliocca, Antonio D\u2019 Onofrio, Paolo Golino, Gerardo Nigro, and Vincenzo Russo have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}